Protagonist Therapeutics' financial profile is dominated by episodic milestone payments, as evidenced by revenue surging to $213.5M in 2026Q2 from $7.4M in 2025Q4, while R&D expenses have steadily climbed to $42.1M. The company maintains a fortress balance she...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue is highly volatile, swinging from $255.0M in 2024Q1 to $4.2M in 2024Q2, with gross margins artificially at 100% due to zero COGS, while R&D expenses have grown 25.7% from $33.5M to $42.1M over the same period.
PTGX's proprietary peptide engineering platform has already demonstrated innovation and execution potential in biotech.
The company's clinical assets are seen as undervalued, offering significant upside potential.
PTGX's strategic optionality, including partnerships or licensing opportunities, adds to its bullish case.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $2.29+2.7% vs $2.23 | $213M+5.3% vs $203M |
Q2 2026 May 5, 2026 | $0.05+107.7% vs -$0.65 | $56M+381.7% vs $12M |
Q1 2026 Feb 25, 2026 | -$0.69-30.2% vs -$0.53 | $7M-14.9% vs $9M |
Q4 2025 Nov 6, 2025 | -$0.62-5.1% vs -$0.59 | $5M-68.4% vs $15M |
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 63,548 shares of the company's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $146.18, for a total transaction of $9,289,446.64. Following the completion of the sale, the chief executive officer directly owned 522,968
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 54,174 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $145.87, for a total transaction of $7,902,361.38. Following the completion of the sale, the chief executive officer directly
Hsbc Holdings PLC raised its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 1,260.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,952 shares of the company's stock after purchasing an additional 24,045 shares during the quarter. Hsbc Holdings PLC's holdings
Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Benchmark PTGX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Protagonist Therapeutics, Inc. (PTGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $138.70 | $8.92B | -67.66 | -89.41% | -282.83% | -20.18% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $8.68 | $454.43M | -1.92 | -92.84% | -80.67% | -14.98% | — | |
| $5.26 | $734.63M | -9.92 | -58.19% | -921.5% | -61.65% | — | |
| $3.48 | $859.66M | -13.38 | 22.09% | -12.35% | -36% | — |
Protagonist Therapeutics, Inc. (PTGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Protagonist Therapeutics, Inc. (PTGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 18, 2026·SEC
May 5, 2026·SEC
Get notified when PTGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Protagonist Therapeutics, Inc. (PTGX) stock FAQ — growth, dividends, profitability & financials explained
Protagonist Therapeutics, Inc. (PTGX) reported $282.0M in revenue for fiscal year 2025.
Protagonist Therapeutics, Inc. (PTGX) saw revenue decline by 89.4% over the past year.
Yes, Protagonist Therapeutics, Inc. (PTGX) is profitable, generating $82.9M in net income for fiscal year 2025 (-282.8% net margin).
Protagonist Therapeutics, Inc. (PTGX) has a return on equity (ROE) of -20.2%. Negative ROE indicates the company is unprofitable.
Protagonist Therapeutics, Inc. (PTGX) generated $83.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
